Bizon Magdalena, Olszewski Maciej, Krason Boguslawa, Kochanowicz Elzbieta, Safiejko Kamil, Borowka Anna, Sekita-Krzak Joanna, Pruc Michal, Drozd Anna, Feduniw Stepan, Cander Basar, Szarpak Lukasz
Department of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.
LUX MED Oncology Hospital, 01-748 Warsaw, Poland.
Int J Mol Sci. 2025 Feb 21;26(5):1841. doi: 10.3390/ijms26051841.
Ovarian cancer is among the most lethal gynecologic malignancies, often diagnosed at advanced stages due to a lack of effective screening tools. Recent studies suggest that the platelet-to-lymphocyte ratio (PLR), an indicator of systemic inflammation, may serve as a potential biomarker for diagnosing and staging ovarian cancer. We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. We searched the PubMed/Medline, Scopus, Web of Science, and EMBASE databases. We pooled data using a random-effects model to assess the sensitivity, specificity, and diagnostic performance of PLR in ovarian cancer. The meta-analysis of 22 studies comprising 5740 participants showed significantly elevated platelet-to-lymphocyte ratio (PLR) values in ovarian cancer patients compared to healthy controls, with a mean difference of 46.84 ( < 0.001). Additionally, PLR demonstrated utility in distinguishing benign from malignant lesions and early-stage from advanced-stage ovarian cancer. While PLR shows potential as a cost-effective and accessible biomarker for ovarian cancer diagnosis and staging, its diagnostic accuracy remains moderate. Therefore, combining PLR with other diagnostic tools enhances clinical decision-making.
卵巢癌是最致命的妇科恶性肿瘤之一，由于缺乏有效的筛查工具，通常在晚期才被诊断出来。最近的研究表明，血小板与淋巴细胞比值（PLR）作为全身炎症的一个指标，可能成为诊断和分期卵巢癌的潜在生物标志物。我们遵循PRISMA指南进行了一项系统评价和荟萃分析。我们检索了PubMed/Medline、Scopus、Web of Science和EMBASE数据库。我们使用随机效应模型汇总数据，以评估PLR在卵巢癌中的敏感性、特异性和诊断性能。对22项研究（共5740名参与者）的荟萃分析显示，与健康对照组相比，卵巢癌患者的血小板与淋巴细胞比值（PLR）值显著升高，平均差异为46.84（<0.001）。此外，PLR在区分良性与恶性病变以及卵巢癌早期与晚期方面具有实用价值。虽然PLR作为一种经济有效且易于获取的卵巢癌诊断和分期生物标志物显示出潜力，但其诊断准确性仍然一般。因此，将PLR与其他诊断工具相结合可提高临床决策水平。
